BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
Status:
Completed
Trial end date:
2016-05-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether it is better to receive a new drug, BBI608,
or better to receive no further treatment for colon or rectal cancer. To do this, half of the
patients in this study will get BBI608 and the other half will receive a placebo (a substance
that is designed not to do anything).
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc